|
|
| Merlin TIMI 36 Trial Primary Results by Dr. David Morrow |
Dr. David Morrow presents the primary results of the Merlin TIMI 36 trial. Ranolazine
lowered the risk of recurrent ischemia, but it did not prolong life or prevent recurrent
heart attacks. These results confirm medical therapy as a valuable treatment for angina as
suggested by the COURAGE trial. Furthermore, this is the first clinical evidence that the
favorable effects of Ranolazine on the electrical system of the heart seen in animals may
be applied to humans.
Keywords: Dr. David Morrow, Ranolazine, Merlin TIMI 36, ischemia,
arrhythmia, angina, COURAGE trial, coronary artery disease, non-ST elevation, medical
therapy
[ Download video ] |
|
No comments have been submitted
|